The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Live Science on MSN
$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...
Bread and biscuits made from Crispr-edited wheat showed substantially reduced acrylamide levels Scientists have developed gene-edited wheat that can be used to make bread that is less carcinogenic ...
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue ...
Artificial intelligence is rapidly learning to autonomously design and run biological experiments, but the systems intended to govern those capabilities are struggling to keep pace.
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP ...
March 27 (Reuters) - A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for a second time in their dispute with the Broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results